X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TD139
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
The webinar will feature a presentation by Key Opinion Leader, who will discuss the current treatment landscape and unmet medical need in treating patients with IPF, as well as the clinical meaning of the exciting biomarker data on GB0139.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TD139
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
The DSMB informed the company imbalance in the serious adverse experiences across the study groups. Galecto expects to continue recruiting patients who are not taking nintedanib or pirfenidone at screening and who would be randomized to receive GB0139 3 mg or placebo.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
